Tanshinone H-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo

Tumori

Volumn 95, Issue 6, 2009, Pages 789-795

  Xu, Yuxian ^a   Tian, Feng ^b   Li, Ren ^c   Liu, Zhengcai ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b The 210th Hospital of PLA   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Liver cancer; Metalloproteinase; Metastasis; Tanshinone II A

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TANSHINONE IIA; ANTINEOPLASTIC AGENT; HERBACEOUS AGENT; MMP2 PROTEIN, HUMAN; PHENANTHRENE DERIVATIVE; TANSHINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL MIGRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; METASTASIS; PATHOLOGY; SALVIA MILTIORRHIZA; SIGNAL TRANSDUCTION; TIME; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NF-KAPPA B; PHENANTHRENES; SALVIA MILTIORRHIZA; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 76349098019     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160909500623     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J: Global cancer statistics, 2000. CA Cancer J Clin, 55: 74-108, 2002.
2. Yuan SL, Wei YQ, Wang XJ, Xiao F, Li SF, Zhang J: Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol, 10: 2024-2028, 2004.
3. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 340: 745-750, 1999.
4. De Vos Irvine H, Goldberg D, Hole DJ, McMenamin J: Trends in primary liver cancer. Lancet, 351: 215-216, 1998.
5. Zhang Q, Kang X, Zhao W: Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun, 342: 824-828, 2006.
6. Kang XM, Zhang QY, Tong DD, Zhao W: Experimental study on anti-angiogenesis in mice with Lewis lung carcinoma by low-dose of cyclophosphamide combined with ginsenoside Rg3. Zhongguo Zhong Xi Yi Jie He Za Zhi, 25: 730-733, 2005.
7. Iishi H, Tatsuta M, Baba M, Uehara H, Nakaizumi A, Shinkai K, Akedo H, Funai H, Ishiguro S, Kitagawa I: Inhibition by ginsenoside Rg3 of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin Exp Metastasis, 15: 603-611, 1997.
8. Chen J, Peng H, Ou-Yang X, He X: Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells. Melanoma Res, 18: 322-329, 2008.
9. Kim HS, Lee EH, Ko SR, Choi KJ, Park JH, Im DS: Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res, 27: 429-435, 2004.
10. Liu WK, Xu SX, Che CT: Anti-proliferative effect of ginseng saponins on human prostate cancer cell line. Life Sci, 67: 1297-1306, 2000.
11. Yuan SL, Huang RM, Wang XJ, Song Y, Huang GQ: Reversing effect of Tanshinone on malignant phenotypes of human hepatocarcinoma cell line. World J Gastroenterol, 4: 317-319, 1998.
12. Yuan SL, Wei YQ, Wang XJ, Xiao F, Li SF, Zhang J: Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol, 10: 2024-2028, 2004.
13. Wu WL, Chang WL, Chen CF: Cytotoxic activities of tanshinones against human carcinoma cell lines. Am J Chin Med, 19: 207-216, 1991.
14. Yoon Y, Kim YO, Jeon WK, Park HJ, Sung HJ: Tanshinone IIA isolated from Salvia miltiorrhiza BUNGE induced apoptosis in HL60 human premyelocytic leukemia cell line. J Ethnopharmacol, 68: 121-127, 1999.
15. Sung HJ, Choi SM, Yoon Y, An KS: Tanshinone IIA, an ingredient of Salvia miltiorrhiza BUNGE, induces apoptosis in human leukemia cell lines through the activation of caspase-3. Exp Mol Med, 31: 174-178, 1999.
16. Ai ZW: Reversing effect of retinoic acid on some phenotypes of human hepatocarcinoma cell line. Zhonghua Zhongliu Zazhi, 13: 9-12, 1991.
17. Haifeng J, Yanglin P, Lijie H, Huihong Z, Xiaohua L, Lina Z, Li S, Jie L, Liu H, Jiugang S, Huahong X, Juan G, Shuang H, Ying L, Daiming F: p75 neurotrophin receptor inhibits invasion and metastasis of gastric cancer. Mol Cancer Res, 5: 423-433, 2007.
18. Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, Gao DM, Ma ZC: Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer, 66: 239-243, 1996.
19. Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, Xue Q: New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer, 81: 814-821, 1999.
20. Kondo S, Kubota S, Shimo T, Nishida T, Yosimichi G, Eguchi T, Sugahara T, Takigawa M: Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases. Carcinogenesis, 23: 769-776, 2002.
21. Pei L, Zhenghuai T, Zhifeng Z, Honghao L, Zhengji M : Inhibitory effects of salvianolic acid B on the high glucose-induced mesangial proliferation via NF-κ B-dependent pathway. Biol Pharm Bull, 31: 1381-1386, 2008.
22. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE: E-cadherin germline mutations in familial gastric cancer. Nature, 392: 402-404, 1998.
23. El-Rifai W, Powell SM: Molecular biology of gastric cancer. Semin Radiat Oncol, 12: 128-140, 2002.
24. Auwardt RB, Mudge SJ, Chen C, Power DA: Inhibition with antisense oligonucleotide suggests that IkappaB-alpha does not form a negative autoregulatory loop for NF-kappaB in mesangial cells. Exp Nephrol, 8: 144-151, 2000.
25. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol, 2: 533-543, 2001.
26. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Uu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol, 130: 187-196, 2004.
27. Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS: High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer, 79: 878-883, 1997.
28. Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Ohtsubo T, Miura S, Narasaka T, Takeyama H, Omata T, Shimokobe K, Ito M, Takehara H, Matsuoka T: Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori. Scand J Gastroenterol, 40: 783-793, 2005.
29. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR: Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer, 75: 721-730, 1998.
30. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S: Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci, 94: 43-49, 2003.
31. Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Matsusaki K, Chayama K, Yasui W: A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol, 131: 19-25, 2005.
32. Alfano D, Franco P, Vocca I, Gambi N, Pisa V, Mancini A, Caputi M, Carriero MV Iaccarino I, Stoppelli MP: The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost, 93: 205-211, 2005.
33. Jin UH, Suh SJ, Chang HW, Son JK, Lee SH, Son KH, Chang YC, Kim CH: Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP-9 activity through AKT signaling pathway. J Cell Biochem, 104: 15-26, 2008.
34. Bours V, Bonizzi G, Bentires-Alj M, Bureau F, Piette J, Lekeux P, Merville M: NF-kappaB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology, 153: 27-38, 2000.
35. Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle PA: Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature, 365: 182-185, 1993.